Filing Analysis
Lucid Diagnostics Inc. reported its financial results for the first fiscal quarter ended March 31, 2026, and provided a concurrent business update.
📋 Key Facts
- The report was filed on May 14, 2026, covering the period ending March 31, 2026.
- The filing includes a press release as Exhibit 99.1 detailing the financial performance.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Lucid Diagnostics Inc. closed a public offering of 18,000,000 shares of common stock at a price of $1.00 per share. The offering resulted in approximately $16.8 million in net proceeds intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant shareholder dilution resulting from the issuance of 18 million new shares.
- The $1.00 price point may represent a discount to the market price depending on the trading history prior to the offering.
📋 Key Facts
- Closed the sale of 18,000,000 shares of common stock on April 24, 2026.
- Offering price was set at $1.00 per share.
- Net proceeds are expected to be approximately $16.8 million after underwriting discounts and expenses.
- Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners.
- The offering was conducted under an existing shelf registration statement on Form S-3 (No. 333-291981).
Lucid Diagnostics Inc. entered into an underwriting agreement for a public offering of 18,000,000 shares of common stock at a price of $1.00 per share. The offering is expected to generate gross proceeds of $18 million before expenses.
🚩 Red Flags
- Significant potential dilution to existing shareholders from the issuance of 18 million new shares.
- The $1.00 offering price suggests the company is operating in a low-share-price environment, which often precedes delisting risks or reverse splits in micro-cap stocks.
📋 Key Facts
- Public offering price set at $1.00 per share.
- Total of 18,000,000 shares of common stock to be sold.
- Gross proceeds of $18,000,000; net proceeds of $0.94 per share after underwriting discounts.
- Underwriters include Canaccord Genuity LLC and BTIG, LLC.
- The offering is expected to close on or about April 24, 2026.
- Offering conducted under an existing shelf registration statement (Form S-3).
Lucid Diagnostics Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. The disclosure was made via a press release on March 26, 2026, and furnished under Items 2.02 and 7.01.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- Filing date: March 26, 2026
- Exhibit 99.1 contains the full press release and business update
- The report was signed by Dennis McGrath, Chief Financial Officer